Literature DB >> 35439252

Correction: Infliximab for pediatric patients with Crohn's disease: A Phase 3, open-label, uncontrolled, multicenter trial in Japan.

Hitoshi Tajiri, Satoshi Motoya, Fukunori Kinjo, Atsuo Maemoto, Takayuki Matsumoto, Noriko Sato, Hiroshi Yamada, Mieko Nagano, Yutaka Susuta, Kunihiko Ozaki, Kazuoki Kondo, Toshifumi Hibi.

Abstract

[This corrects the article DOI: 10.1371/journal.pone.0201956.].

Entities: Chemical

Year: 2022 PMID： 35439252 PMCID： PMC9017882 DOI： 10.1371/journal.pone.0261932

Source DB: PubMed Journal: PLoS One ISSN： 1932-6203 Impact factor: 3.240

An incorrect version of S1 File was published as two separate Supporting Information documents (S1 and S2 Files in the original article) in error. Please view the correct S1 File below.

Protocol summary in English.

(PDF) Click here for additional data file.

1 in total

1. Infliximab for pediatric patients with Crohn's disease: A Phase 3, open-label, uncontrolled, multicenter trial in Japan.

Authors: Hitoshi Tajiri; Satoshi Motoya; Fukunori Kinjo; Atsuo Maemoto; Takayuki Matsumoto; Noriko Sato; Hiroshi Yamada; Mieko Nagano; Yutaka Susuta; Kunihiko Ozaki; Kazuoki Kondo; Toshifumi Hibi
Journal: PLoS One Date: 2018-08-16 Impact factor: 3.240

1 in total